NCT04464733View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics(PK), Pharmacodynamics(PD) and Food Effect of HRS9950 in Healthy and CHB Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

July 20, 2020

Primary Completion Date

May 30, 2023

Study Completion Date

May 30, 2023

Conditions
Chronic Hepatitis b
Interventions
DRUG

HRS9950

HRS9950

DRUG

Placebo

Placebo

Trial Locations (1)

100069

Beijing Youan Hospital,Capital Medical University, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04464733 - Safety, Tolerability, Pharmacokinetics(PK), Pharmacodynamics(PD) and Food Effect of HRS9950 in Healthy and CHB Subjects | Biotech Hunter | Biotech Hunter